WO2014136932A1 - 抗炎症剤 - Google Patents
抗炎症剤 Download PDFInfo
- Publication number
- WO2014136932A1 WO2014136932A1 PCT/JP2014/055932 JP2014055932W WO2014136932A1 WO 2014136932 A1 WO2014136932 A1 WO 2014136932A1 JP 2014055932 W JP2014055932 W JP 2014055932W WO 2014136932 A1 WO2014136932 A1 WO 2014136932A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inflammatory
- lactoadherin
- inflammatory agent
- degradation product
- lactadherin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the present invention has an excellent effect of suppressing the production of inflammatory cytokines, improves excessive inflammation in the living body, is useful for prevention and treatment of collagen diseases, allergic diseases, metabolic diseases, infectious diseases, and the like, and is stable and safe. It is related with the anti-inflammatory agent excellent in the property.
- the present invention further relates to an anti-inflammatory food, beverage, anti-inflammatory nutrition composition, or anti-inflammatory feed containing an anti-inflammatory agent.
- Inflammatory cytokines are substances that are produced from lymphocytes, macrophages, and the like and are involved in inflammatory reactions associated with bacterial and viral infections, tumors, and tissue damage.
- interleukin-1 IL-1
- IL-6 interleukin-6
- TNF- ⁇ tumor necrosis factor
- GM-CSF GM-CSF
- chemokine such as MCP-1 induces inflammation by causing neutrophils, monocytes, or lymphocytes to migrate to the inflamed site.
- pathological conditions caused by excessive production of inflammatory cytokines include systemic inflammatory response syndrome, collagen diseases such as rheumatoid arthritis and allergic diseases, as well as metabolic diseases such as arteriosclerosis, insulin resistance, and diabetes.
- Infectious diseases such as multiple sclerosis, graft-versus-host disease, viral hepatitis, HIV infection, etc., suppressing the production of inflammatory cytokines is very useful for the prevention, treatment, improvement and prevention of recurrence of these conditions It has been reported that.
- antihistamines and steroids are known as drugs for suppressing excessive inflammation in the living body, but when these drugs are used, side effects such as tinnitus, headache, and loss of appetite are involved. There is. Furthermore, these substances cannot be added to food and drink at present from the viewpoints of safety and cost. Therefore, development of food and drink and feed that can be safely ingested on a daily basis and that can suppress excessive production of inflammatory cytokines is desired.
- Lactoadherin is one of the glycoproteins that make up the fat globule membrane of milk, and in milk it accounts for about 10% of the protein contained in the fat globule membrane. Its molecular weight is 43 kDa to 53 kDa, its isoelectric point is 7.0, and it has two epidermal growth factor-like domains.
- lactadherin is also referred to as PAS-VI-VII (PAS6 / 7) in cattle, and lactadherin contained in mouse milk is also expressed as MFG-E8.
- lactoadherin is thought to play a role in regulating the gastrointestinal function of newborns, and is blended in infant formula for the purpose of preventing infection of newborns with rotavirus.
- sphingomyelin, lactoperoxidase, and acidic xylooligosaccharides are known as food ingredients that suppress excessive production of inflammatory cytokines.
- lactoadherin and / or a degradation product thereof is excellent in the effect of suppressing the production of inflammatory cytokines and improves excessive inflammation in the living body.
- the present invention has a remarkable effect of suppressing the production of inflammatory cytokines, and is effective in preventing or treating collagen diseases, allergic diseases, metabolic diseases, infectious diseases, etc. by improving excessive inflammation in the living body. It is an object to provide an anti-inflammatory food and drink, an anti-inflammatory nutrition composition, or an anti-inflammatory feed containing an agent and an anti-inflammatory agent.
- lactadherin and / or a degradation product thereof have an excellent inflammatory cytokine production inhibitory effect. That is, the present invention includes the following modes. (1) An anti-inflammatory agent comprising lactoadherin and / or a degradation product thereof as an active ingredient. (2) The anti-inflammatory agent according to (1), wherein the lactoadherin and / or a degradation product thereof is derived from milk. (3) The anti-inflammatory agent according to (1) or (2), wherein the lactoadherin degradation product is a product obtained by degrading lactoadherin using a proteolytic enzyme.
- the anti-inflammatory agent according to (3) wherein the proteolytic enzyme is at least one selected from the group consisting of trypsin, pancreatin, chymotrypsin, pepsin, and papain.
- An anti-inflammatory food, beverage, anti-inflammatory nutrition composition, or anti-inflammatory feed comprising the anti-inflammatory agent according to any one of (1) to (4).
- the anti-inflammatory agent of the present invention has a remarkable effect of suppressing the production of inflammatory cytokines, and is useful for the prevention and treatment of collagen diseases, allergic diseases, metabolic diseases, infectious diseases and the like.
- lactadherin which is an active ingredient of an anti-inflammatory agent, includes (A) buttermilk, which is an aqueous phase component produced when producing butter from raw milk, and (B) fat content 40 to 40 obtained by separator separation of raw milk. Heat treatment or shearing treatment is performed on 60% or more high fat cream obtained by separating 50% cream with a separator again, and the water phase component discharged when the high fat cream is phase-inverted, or ( C) Detach butaselam, which is an aqueous phase component that separates when butter is heated and dissolved, using an ultrafiltration (UF) membrane, microfiltration (MF) membrane, reverse osmosis membrane (RO) membrane, ion exchange resin, etc. It can be obtained by salting or concentrating.
- UF ultrafiltration
- MF microfiltration
- RO reverse osmosis membrane
- ion exchange resin ion exchange resin
- a lactoadherin degradation product that is an active ingredient of an anti-inflammatory agent can be obtained by degrading the above-mentioned lactoadherin with any proteolytic enzyme.
- Proteolytic enzymes include protease A “Amano” SD (trade name), Samoase PC10F (trade name), protin SD-AY10 (trade name) and other commercially available food and industrial protease agents, trypsin, pancreatin, Examples include chymotrypsin, pepsin, papain and the like, and a plurality of these may be used in combination.
- the lactoadherin and / or its degradation product prepared as described above can be dried by freeze drying, spray drying, or the like.
- Lactoadherin and / or its degradation products are prepared from milk of mammals such as humans, cows, buffalos, goats, sheep, etc., produced by genetic engineering techniques, purified from blood and organs, etc. Can be used. This is because it can be produced simply and economically and can be safely taken on a daily basis. Of these, those derived from milk are preferred. It is also possible to use a purified and commercially available reagent for lactoadherin and / or its degradation product.
- Lactoadherin and / or its degradation product may be used as it is as an anti-inflammatory agent, but if necessary, it can be formulated into powders, granules, tablets, capsules, drinks, etc. according to conventional methods. It can also be used.
- lactadherin and / or a degradation product thereof dried by freeze drying, spray drying or the like can be used as an anti-inflammatory agent as it is, and can be formulated and used according to a conventional method. Furthermore, after formulating these, it is also possible to mix this with foods and beverages such as nutrients, yogurt, beverages, wafers, nutritional compositions or feeds.
- Anti-inflammatory food and beverage, anti-inflammatory nutrition composition and anti-inflammatory feed include, in addition to this lactoadherin and / or its degradation products, stabilizers, sugars, lipids, flavors, vitamins, minerals, flavonoids, polyphenols Etc., and other raw materials usually contained in foods and drinks can be contained. Moreover, in addition to the active ingredient lactoadherin and / or its degradation product, it can also be used together with a component exhibiting an anti-inflammatory action, for example, sphingomyelin, lactoperoxidase, acidic xylooligosaccharide and the like.
- the amount of lactadherin and / or its degradation product in the anti-inflammatory food, beverage, anti-inflammatory nutrition composition and anti-inflammatory feed is not particularly limited, but the present invention has the effect of suppressing the production of inflammatory cytokines.
- An anti-inflammatory agent can be formulated into an arbitrary form by adding an appropriate auxiliary agent to lactadherin which is an active ingredient and / or a degradation product thereof.
- diluents or excipients such as fillers, extenders, binders, disintegrants, surfactants, lubricants and the like that are usually used can be used.
- the excipient include sucrose, lactose, starch, crystalline cellulose, mannitol, light anhydrous silicic acid, magnesium aluminate, synthetic aluminum silicate, magnesium magnesium metasilicate, calcium carbonate, sodium hydrogen carbonate, calcium hydrogen phosphate
- carboxymethylcellulose calcium and the like can be added in combination.
- an anti-inflammatory agent in which an anti-inflammatory agent containing lactoadherin and / or a degradation product thereof described in the embodiments as an active ingredient is applied to an inflammatory patient.
- an anti-inflammatory agent containing lactoadherin and / or a degradation product thereof described in the embodiments as an active ingredient
- an anti-inflammatory agent for example, those isolated and purified from the raw materials as described in the Examples section below can be used.
- Anti-inflammatory agents can also be applied to humans and other mammals such as dogs, monkeys, cats, cattle, horses, pigs, chickens, sheep and other livestock.
- the powder of lactoadherin prepared in Example 1 was dissolved in 100 ml of purified water, and the pH was adjusted to 8 using sodium bicarbonate. Thereafter, trypsin (manufactured by Sigma) as a proteolytic enzyme was added to a final concentration of 0.01%, followed by enzyme treatment at 37 ° C. for 1 hour. And after heat-processing at 85 degreeC for 10 minute (s), the enzyme was deactivated, it lyophilized
- the molecular weight of the thus obtained lactoadherin degradation product is 5 kDa or less, and can be used as it is as an anti-inflammatory agent.
- Example 1 The effects of the lactoadherin obtained in Example 1 and the lactoadherin degradation product obtained in Example 2 on the production of IL-6 and IL-8, which are inflammatory cytokines, were examined.
- Human colon adenocarcinoma cell line Caco-2 showing small intestinal epithelial cell-like characteristics was seeded in a 24-well microtiter plate and cultured in Dulbecco's modified basic medium (DMEM) containing 10% fetal bovine serum for 2 weeks.
- DMEM Dulbecco's modified basic medium
- Example 2 the powder of lactoadherin obtained in Example 1 (final concentration: 0.5, 5, 50, 500 ⁇ g / ml as lactoadherin) or the lactoadherin degradation product obtained in Example 2 Powder (final concentration: 0.5, 5, 50, 500 ⁇ g / ml as a lactoadherin degradation product) was added and cultured for 12 hours. Further, as a positive target, lactoperoxidase (final concentration: 5,50,500 ⁇ g / ml as lactoperoxidase) was added and cultured for 12 hours.
- IL-1 ⁇ final concentration 0.2 ng / ml
- the concentration was measured by ELISA. The results are shown in Tables 1 and 2.
- lactoperoxidase was orally administered at a dose of 50 mg / kg body weight in the same manner.
- 0.1 ml of ⁇ -carrageenan suspended at 1% by weight in physiological saline as an inflammatory substance was subcutaneously injected into the right hind footpad of the rat to induce edema.
- the area of the right hind footpad was measured, and the rate of increase in the footpad volume (V1) was determined.
- Example product 1 (Preparation of liquid nutritional composition for anti-inflammatory) 50 g of Example product 1 was dissolved in 4,950 g of deionized water, heated to 50 ° C., and then stirred and mixed at 6,000 rpm for 30 minutes with a TK homomixer (TK ROBO MICS; manufactured by Tokushu Kika Kogyo Co., Ltd.). Thus, a lactoadherin solution having a lactoadherin content of 39 g / 5 kg was obtained.
- TK ROBO MICS manufactured by Tokushu Kika Kogyo Co., Ltd.
- Example Product 1 2 kg was dissolved in 98 kg of deionized water, heated to 50 ° C., and then stirred and mixed at 3,600 rpm for 40 minutes with a TK homomixer (MARK II 160 type; manufactured by Tokushu Kika Kogyo Co., Ltd.). A lactoadherin solution having a lactoadherin content of 1.56 g / 100 g was obtained.
- TK homomixer MARK II 160 type; manufactured by Tokushu Kika Kogyo Co., Ltd.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Husbandry (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Marine Sciences & Fisheries (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Fodder In General (AREA)
Abstract
Description
これまで、炎症性サイトカインの過剰な産生を抑制する食品成分として、スフィンゴミエリンやラクトパーオキシダーゼ、酸性キシロオリゴ糖が知られている。しかしながら、ラクトアドヘリン及び/又はその分解物が炎症性サイトカインの産生を抑制する効果に優れ、生体における過剰な炎症を改善することは知られていない。
すなわち本発明は、以下の様態を含むものである。
(1)ラクトアドヘリン及び/又はその分解物を有効成分とする抗炎症剤。
(2)ラクトアドヘリン及び/又はその分解物が牛乳由来である(1)に記載の抗炎症剤。
(3)ラクトアドヘリン分解物が、ラクトアドヘリンをタンパク質分解酵素を用いて分解したものである(1)又は(2)に記載の抗炎症剤。
(4)タンパク質分解酵素が、トリプシン、パンクレアチン、キモトリプシン、ペプシン、パパインからなる群から選択される少なくとも1種である(3)に記載の抗炎症剤。
(5)(1)から(4)のいずれか1つに記載の抗炎症剤を含む抗炎症用飲食品、抗炎症用栄養組成物又は抗炎症用飼料。
(6)(1)から(4)のいずれか1つに記載の抗炎症剤を経口摂取することによる生体における炎症改善方法。
(7)ラクトアドヘリン及び/又はその分解物を有効成分とする抗炎症剤を、炎症患者に適用する抗炎症剤の使用方法。
さらに、これらを製剤化した後に、これを栄養剤やヨーグルト、飲料、ウエハース等の飲食品、栄養組成物又は飼料に配合することも可能である。
例えば、実施形態において説明したラクトアドヘリン及び/又はその分解物を有効成分とする抗炎症剤を、炎症患者に適用する抗炎症剤の使用方法が提供される。この場合、ラクトアドヘリン及び/又はその分解物としては、例えば、後述の実施例の欄で説明するようにして原料から単離、精製されたものを用いることができる。また抗炎症剤は、ヒトその他の哺乳類、例えば犬、サル、ネコ、牛、馬、豚、鶏、羊等の家畜にも適用され得る。
実施例1で得られたラクトアドヘリン及び実施例2で得られたラクトアドヘリン分解物が、炎症性サイトカインであるIL-6とIL-8の産生を抑制する効果を調べた。小腸上皮細胞様の特徴を示すヒト結腸腺癌細胞株Caco-2を、24穴のマイクロタイタープレートに播種し、10%ウシ胎児血清を含有するダルベッコ変法基礎培地(DMEM)で2週間培養した後、実施例1で得られたラクトアドヘリンの粉末(終濃度:ラクトアドヘリンとして、0.5,5,50,500μg/ml)又は、実施例2で得られたラクトアドヘリン分解物の粉末(終濃度:ラクトアドヘリン分解物として、0.5,5,50,500μg/ml)を添加し、12時間培養した。また、陽性対象として、ラクトパーオキシダーゼ(終濃度:ラクトパーオキシダーゼとして、5,50,500μg/ml)を添加し、12時間培養した。その後、それぞれに、IL-1β(終濃度0.2ng/ml)を添加して24時間培養した後、培養上清を回収して、培養上清中に含まれるIL-6濃度とIL-8濃度をELISA法で測定した。その結果を、表1と表2に示す。
ラクトアドヘリン及びラクトアドヘリン分解物の抗炎症効果を特開2007-112793に記載の方法により、カラゲニン誘発ラット足浮腫モデルを用いて調べた。すなわち、ウイスター系雄ラット(体重:110~130g、1群:10匹)に、実施例1で得られたラクトアドヘリンの粉末と実施例3で得られたラクトアドヘリン分解物の粉末を、それぞれ、体重1kgあたり、ラクトアドヘリン又はラクトアドヘリン分解物として、5mg又は50mgになるように0.5重量%のカルボキシメチルセルロース水溶液に懸濁して経口投与した。また、陽性対象として、同様の方法で、ラクトパーオキシダーゼを体重1kgあたり50mgになるように経口投与した。その1時間後に、起炎物質として生理食塩水に1重量%になるように懸濁したλ-カラゲニンを、ラットの右後肢足蹠に0.1ml皮下注入して浮腫を惹起させた。λ-カラゲニン注入前ならびに注入5時間後に、それぞれ右後肢足蹠の面積を測定し、足蹠容量の増加率(V1)を求めた。陰性対象として、ラクトアドヘリンやその分解物、ラクトパーオキシダーゼを含有しない0.5重量%のカルボキシメチルセルロース水溶液のみを経口投与したラットに、起炎物質として生理食塩水に1重量%になるように懸濁したλ-カラゲニンを、ラットの右後肢足蹠に0.1ml皮下注入した際の足蹠容量の増加率(V0)を測定し、(V0-V1)/V0×100の計算式により、カラゲニン浮腫抑制率を算出した。したがって、この値が大きいほど、抗炎症効果が高いことを示す。その結果を表3に示す。
表4に示す配合で原材料を混合後、常法により造粒し、カプセルに充填して、抗炎症用カプセル剤を製造した。
表5に示す配合で原材料を混合後、常法により1gに成型、打錠して抗炎症用錠剤を製造した。
50gの実施例品1を4,950gの脱イオン水に溶解し、50℃まで加熱後、TKホモミクサー(TK ROBO MICS;特殊機化工業社製)にて、6,000rpmで30分間撹拌混合してラクトアドヘリン含量39g/5kgのラクトアドヘリン溶液を得た。このラクトアドヘリン溶液5.0kgに、カゼイン5.0kg、大豆タンパク質5.0kg、魚油1.0kg、シソ油3.0kg、デキストリン17.0kg、ミネラル混合物6.0kg、ビタミン混合物1.95kg、乳化剤2.0kg、安定剤4.0kg、香料0.05kgを配合し、200mlのレトルトパウチに充填し、レトルト殺菌機 (第1種圧力容器、TYPE: RCS-4CRTGN、日阪製作所製)で121℃、20分間殺菌して、抗炎症用液状栄養組成物50kgを製造した。
脱脂粉乳300gを409gの脱イオン水に溶解した後、実施例品3、1gを溶解し、50℃まで加熱後、ウルトラディスパーサー(ULTRA-TURRAX T-25;IKAジャパン社製)にて、9,500rpmで30分間撹拌混合した。マルチトール100g、酸味料2g、還元水飴20g、香料2g、脱イオン水166gを添加した後、100mlのガラス瓶に充填し、95℃、15秒間殺菌後、密栓し、抗炎症用飲料10本(100ml入り)を調製した。
2kgの実施例品1を98kgの脱イオン水に溶解し、50℃まで加熱後、TKホモミクサー(MARK II 160型;特殊機化工業社製)にて、3,600rpmで40分間撹拌混合してラクトアドヘリン含量1.56g/100gのラクトアドヘリン溶液を得た。このラクトアドヘリン溶液10kgに大豆粕12kg、脱脂粉乳14kg、大豆油4kg、コーン油2kg、パーム油23.2kg、トウモロコシ澱粉14kg、小麦粉9kg、ふすま2kg、ビタミン混合物5kg、セルロース2.8kg、ミネラル混合物2kgを配合し、120℃、4分間殺菌して、抗炎症用飼料100kgを製造した。
Claims (7)
- ラクトアドヘリン及び/又はその分解物を有効成分とする抗炎症剤。
- 前記ラクトアドヘリン及び/又はその分解物が牛乳由来である請求項1に記載の抗炎症剤。
- 前記ラクトアドヘリン分解物が、ラクトアドヘリンをタンパク質分解酵素を用いて分解したものである請求項1又は請求項2に記載の抗炎症剤。
- 前記タンパク質分解酵素が、トリプシン、パンクレアチン、キモトリプシン、ペプシン、パパインからなる群から選択される少なくとも1種である請求項3記載の抗炎症剤。
- 請求項1から請求項4のいずれか1項に記載の抗炎症剤を含む抗炎症用飲食品、抗炎症用栄養組成物又は抗炎症用飼料。
- 請求項1から請求項4のいずれか1項に記載の抗炎症剤を経口摂取することによる生体における炎症改善方法。
- ラクトアドヘリン及び/又はその分解物を有効成分とする抗炎症剤を、炎症患者に適用する抗炎症剤の使用方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201480013137.9A CN105025915A (zh) | 2013-03-08 | 2014-03-07 | 抗炎剂 |
AU2014226865A AU2014226865B2 (en) | 2013-03-08 | 2014-03-07 | Anti-inflammatory agent |
HK15112699.2A HK1211843A1 (en) | 2013-03-08 | 2015-12-24 | Anti-inflammatory agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013046736A JP2014172861A (ja) | 2013-03-08 | 2013-03-08 | 抗炎症剤 |
JP2013-046736 | 2013-03-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014136932A1 true WO2014136932A1 (ja) | 2014-09-12 |
Family
ID=51491439
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2014/055932 WO2014136932A1 (ja) | 2013-03-08 | 2014-03-07 | 抗炎症剤 |
Country Status (6)
Country | Link |
---|---|
JP (1) | JP2014172861A (ja) |
CN (1) | CN105025915A (ja) |
AU (1) | AU2014226865B2 (ja) |
HK (1) | HK1211843A1 (ja) |
TW (1) | TW201511769A (ja) |
WO (1) | WO2014136932A1 (ja) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011151341A1 (en) * | 2010-05-31 | 2011-12-08 | Rotalactis Srl | Lactadherin-derived peptides as antiviral agents |
WO2012149254A2 (en) * | 2011-04-28 | 2012-11-01 | The Feinstein Institute For Medical Research | Mfg-e8 and uses thereof |
WO2012170021A1 (en) * | 2011-06-08 | 2012-12-13 | Nestec S.A. | Nutritional compositions having exogenous milk fat globule membrane components |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101869151B (zh) * | 2010-07-08 | 2012-07-04 | 湖南澳优食品与营养研究院 | 一种含乳凝集素的婴幼儿奶粉及其制备方法 |
-
2013
- 2013-03-08 JP JP2013046736A patent/JP2014172861A/ja active Pending
-
2014
- 2014-03-07 AU AU2014226865A patent/AU2014226865B2/en not_active Ceased
- 2014-03-07 CN CN201480013137.9A patent/CN105025915A/zh active Pending
- 2014-03-07 WO PCT/JP2014/055932 patent/WO2014136932A1/ja active Application Filing
- 2014-03-10 TW TW103108240A patent/TW201511769A/zh unknown
-
2015
- 2015-12-24 HK HK15112699.2A patent/HK1211843A1/xx unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011151341A1 (en) * | 2010-05-31 | 2011-12-08 | Rotalactis Srl | Lactadherin-derived peptides as antiviral agents |
WO2012149254A2 (en) * | 2011-04-28 | 2012-11-01 | The Feinstein Institute For Medical Research | Mfg-e8 and uses thereof |
WO2012170021A1 (en) * | 2011-06-08 | 2012-12-13 | Nestec S.A. | Nutritional compositions having exogenous milk fat globule membrane components |
Non-Patent Citations (5)
Title |
---|
"Bonyu Science Milk Meiji Hohoemi", JAPAN FOOD JOURNAL, 16 February 2005 (2005-02-16) * |
"Yuki Jirushi Tacchi", MEGMILK SNOW BRAND NO KONA MILK, 2011, Retrieved from the Internet <URL:http://www.snowbaby.jp/tacchi> [retrieved on 20140501] * |
DEROIDE, N. ET AL.: "MFGE8 inhibits inflammasome-induced IL -1beta production and limits postischemic cerebral injury", J. CLIN. INVEST., vol. 123, no. 3, pages 1176 - 1181 * |
OTANI, A. ET AL.: "Intrarectal administration of milk fat globule epidermal growth factor-8 protein ameliorates murine experimental colitis", INT. J. MOL. MED., vol. 29, no. 3, March 2012 (2012-03-01), pages 349 - 356 * |
ZHANG, F. ET AL.: "Milk fat globule epidermal growth factor-factor 8 mitigates inflammation and tissue injury after hemorrhagic shock in experimental animals", J. TRAUMA ACUTE CARE SURG., vol. 72, no. 4, April 2012 (2012-04-01), pages 861 - 869 * |
Also Published As
Publication number | Publication date |
---|---|
CN105025915A (zh) | 2015-11-04 |
JP2014172861A (ja) | 2014-09-22 |
AU2014226865A1 (en) | 2015-10-01 |
AU2014226865B2 (en) | 2018-09-13 |
TW201511769A (zh) | 2015-04-01 |
HK1211843A1 (en) | 2016-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20110319315A1 (en) | Muscle-building agent | |
AU2009205116B2 (en) | Liver function-protecting agent | |
EP2039365A1 (en) | Visceral fat accumulation inhibitor, and agent for promoting the increase in and/or inhibiting the decrease in blood adiponectin level | |
EP2208734B1 (en) | Food material for inhibiting the formation of osteoclast | |
JP6203724B2 (ja) | 骨疾患の予防又は治療用タンパク質素材及びその製造方法 | |
TWI566704B (zh) | 骨強化劑、使用該骨強化劑之製品及骨強化方法 | |
JPWO2009057281A1 (ja) | 骨芽細胞分化促進及び破骨細胞分化抑制用食品素材 | |
JP2004115509A (ja) | 破骨細胞分化抑制因子産生促進剤 | |
JP7372046B2 (ja) | ペプチド | |
WO2014136932A1 (ja) | 抗炎症剤 | |
JP5969225B2 (ja) | 骨強化剤 | |
JPWO2009057282A1 (ja) | 骨吸収抑制用食品素材 | |
EP2534963A1 (en) | Protein synthesis promoter | |
AU2014226864B2 (en) | Infection protection agent | |
JP6203723B2 (ja) | 骨疾患の予防又は治療用タンパク質素材及びその製造方法 | |
JP6357265B2 (ja) | 骨疾患の予防又は治療用タンパク質素材 | |
JP6357266B2 (ja) | 骨疾患の予防又は治療用タンパク質素材 | |
JP5344669B2 (ja) | 内臓脂肪蓄積抑制剤 | |
JP2007223910A (ja) | 抗炎症剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201480013137.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14759873 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2014226865 Country of ref document: AU Date of ref document: 20140307 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: IDP00201506388 Country of ref document: ID |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14759873 Country of ref document: EP Kind code of ref document: A1 |